Seeking Alpha

"We expect upside for shares on this derisking event," Wells Fargo says, referencing data...

"We expect upside for shares on this derisking event," Wells Fargo says, referencing data released today by Celgene (CELG +7%) on Revlimid's performance in Phase III multiple myeloma trials. "We would remain buyers," analyst Brian Abrahams notes, adding that he "expects favorable detailed data at ASH."
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|